Verastem (NASDAQ:VSTM – Free Report) had its price objective reduced by Royal Bank of Canada from $16.00 to $13.00 in a research report sent to investors on Friday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.
Several other equities analysts also recently issued reports on VSTM. Alliance Global Partners cut their price target on shares of Verastem from $34.00 to $20.00 and set a buy rating for the company in a report on Wednesday, May 29th. Truist Financial decreased their price objective on shares of Verastem from $34.00 to $18.00 and set a buy rating for the company in a report on Monday, July 8th. B. Riley decreased their price objective on shares of Verastem from $21.00 to $7.00 and set a buy rating for the company in a report on Wednesday, July 24th. StockNews.com cut shares of Verastem from a hold rating to a sell rating in a report on Thursday, August 1st. Finally, HC Wainwright reiterated a buy rating and issued a $17.50 price target on shares of Verastem in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $19.79.
Check Out Our Latest Report on VSTM
Verastem Price Performance
Verastem (NASDAQ:VSTM – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.10). Equities analysts expect that Verastem will post -4 EPS for the current fiscal year.
Hedge Funds Weigh In On Verastem
Several institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new position in shares of Verastem in the second quarter valued at about $82,000. Rhumbline Advisers grew its stake in Verastem by 4,172.0% during the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 28,119 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Verastem during the second quarter worth about $203,000. Vanguard Group Inc. grew its stake in Verastem by 0.9% during the first quarter. Vanguard Group Inc. now owns 1,160,931 shares of the biopharmaceutical company’s stock worth $13,699,000 after buying an additional 10,678 shares in the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in Verastem during the first quarter worth about $131,000. 88.37% of the stock is currently owned by institutional investors and hedge funds.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Featured Articles
- Five stocks we like better than Verastem
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- The How and Why of Investing in Gold Stocks
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.